Hypoimmune, Allogeneic CD22-Directed CAR T Cells That Evade Innate and Adaptive Immune Rejection for the Treatment of Large B Cell Lymphoma Patients That Are Relapsed/Refractory to CD19-Directed CAR T Cell TherapyAdam Johnson, Terry J. Fry, Neal Van Hoeven et al.|Blood|2023Cited by 4
<i>In Vitro and In Vivo</i> Specificity and Biodistribution of a Novel CD8-Targeted FusosomeHemantkumar Chavan, Sundeep Chandra, Shirisha Amatya et al.|Blood|2023Cited by 2